77Z-15556-00681
4 vaccinations
9 coded responses
23 check-ins
9 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 61-65
- ZIP prefix
- 300 / GA
- Registered
- 2021-08-05
- Relationship
- Self
- Race
- Other
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-11
Dose 1 — Pfizer-BioNTech
-
2021-03-05
Dose 2 — Pfizer-BioNTech
-
2021-08-05
Registered in v-safe
- 2021-09-03
-
2021-09-22
Dose 3 — Pfizer-BioNTech
- 2021-10-02
- 2021-10-06
-
2021-10-13
Survey response — day 21, dose 3MedDRA: Breast tenderness, Unevaluable event — Feeling: Good · Get care from a doctor or other healthcare professionalFree text: Symptoms: Left breast tenderness · Healthcare visit (other): Breast ultrasound scheduledMedDRA releases: 2024-11 · check-in free text available
-
2021-10-13
Report sent to call center — day 21, dose 3Get care from a doctor or other healthcare professional1 call case(s)
- 2021-10-20
- 2021-10-27
- 2021-11-03
-
2021-11-19
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
-
2021-12-22
Survey response — 3 months, dose 3MedDRA: Lymph node pain, Lymphadenopathy — Feeling: FairFree text: Swollen lymph nodes on right side non tender no feverMedDRA releases: 2024-11 · check-in free text available
- 2022-03-23
-
2022-04-14
Dose 4 — Pfizer-BioNTech
-
2022-04-16
Survey response — days 1–6 daily, dose 4MedDRA: Axillary pain, Dizziness — Feeling: Fair · Site: Pain · Fatigue or tiredness, Diarrhea · Be unable to do your normal daily activitiesFree text: pain in both axilla dizzinessMedDRA releases: 2024-11 · check-in free text available
-
2022-04-17
Survey response — days 1–6 daily, dose 4MedDRA: Dizziness postural — Feeling: Fair · Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: some dizziness on standingMedDRA releases: 2024-11 · check-in free text available
-
2022-04-18
Survey response — days 1–6 daily, dose 4MedDRA: Injection site bruising, Injection site discolouration — Feeling: Fair · Site: Pain · Fatigue or tirednessFree text: bruise/discoloration @3cm at injection siteMedDRA releases: 2024-11 · check-in free text available
-
2022-04-19
Survey response — days 1–6 daily, dose 4MedDRA: Dizziness exertional, Loss of personal independence in daily activities — Feeling: Fair · Headache, Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: dizziness with walking Not walking outside and not drivingMedDRA releases: 2024-11 · check-in free text available
-
2022-04-20
Survey response — days 1–6 daily, dose 4MedDRA: No adverse event — Feeling: Good · Rash, not including the immediate area around the injection siteFree text: NoMedDRA releases: 2024-11 · check-in free text available
-
2022-04-21
Survey response — day 7, dose 4MedDRA: Injection site bruising, Injection site discolouration — Feeling: Good · Site: PainFree text: the injection site is "bruised and consistent with a five day bruise with some yellow green discoloration @ 4 cm radiusMedDRA releases: 2024-11 · check-in free text available
- 2022-04-28
- 2022-05-05
- 2022-05-12
- 2022-05-19
-
2022-05-26
Survey response — day 42, dose 4MedDRA: Exposure to SARS-CoV-2, Hypertension, Office visit, Quarantine, SARS-CoV-2 test negative — Feeling: Good · Get care from a doctor or other healthcare professionalFree text: Symptoms: Hypertension New medications Amlodipine Atorvastatin increased dosage of Hydrocho thiazide Daughter in household dx Covid and treated with Paxlovid household on quarantine I have test negative last time on 5/25/2020 · Healthcare visit (other): primary care and CardiologyMedDRA releases: 2024-11 · check-in free text available
-
2022-05-26
Report sent to call center — day 42, dose 4Get care from a doctor or other healthcare professional1 call case(s)
-
2022-05-27
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
- 2022-07-14
- 2022-10-13
- 2023-04-14
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-11 | Pfizer-BioNTech | No |
| 2 | 2021-03-05 | Pfizer-BioNTech | No |
| 3 | 2021-09-22 | Pfizer-BioNTech | No |
| 4 | 2022-04-14 | Pfizer-BioNTech | No |
Call center
2 call center cases
2 successful
Free text
Release 10 — day 21, dose 3
Release 10 — 3 months, dose 3
Symptoms: Swollen lymph nodes on right side non tender no fever
Release 11 — days 1–6 daily, dose 4
Systemic reaction (other): pain in both axilla dizziness
Systemic reaction (other): some dizziness on standing
Systemic reaction (other): bruise/discoloration @3cm at injection site
Systemic reaction (other): dizziness with walking Not walking outside and not driving
Systemic reaction (other): No
Release 11 — day 7, dose 4
Systemic reaction (other): the injection site is "bruised and consistent with a five day bruise with some yellow green discoloration @ 4 cm radius
Release 11 — day 42, dose 4
Symptoms: Hypertension New medications Amlodipine Atorvastatin increased dosage of Hydrocho thiazide Daughter in household dx Covid and treated with Paxlovid household on quarantine I have test negative last time on 5/25/2020
Healthcare visit (other): primary care and Cardiology
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Office visit | · | · | ✓ |
| HCVO | Unevaluable event | · | · | ✓ |
| SD | Breast tenderness | · | · | ✓ |
| SD | Exposure to SARS-CoV-2 | · | · | ✓ |
| SD | Hypertension | · | · | ✓ |
| SD | Lymph node pain | · | · | ✓ |
| SD | Lymphadenopathy | · | · | ✓ |
| SD | Quarantine | · | · | ✓ |
| SD | SARS-CoV-2 test negative | · | · | ✓ |
| SRO | Axillary pain | · | · | ✓ |
| SRO | Dizziness | · | · | ✓ |
| SRO | Dizziness exertional | · | · | ✓ |
| SRO | Dizziness postural | · | · | ✓ |
| SRO | Injection site bruising | · | · | ✓ |
| SRO | Injection site discolouration | · | · | ✓ |
| SRO | Loss of personal independence in daily activities | · | · | ✓ |
| SRO | No adverse event | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release